14-17 June 2017, Lugano
![]() |
![]() |
![]() |
![]() |
140-P | Whole-exome-sequencing of nodal marginal zone lymphomas identifies recurrent molecular lesions in genes involved in chromatin remodelling and NOTCH signalling | Vincent Pillonel | ![]() |
![]() |
|||
141-P | Integrative mutational analysis of Pediatric-Type Follicular Lymphoma reveals TNFRSF14 and MAP2K1 as the most frequently mutated genes | Janine Schmidt | ![]() |
![]() |
|||
143-P | NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY | Simone Ferrero | ![]() |
![]() |
|||
144-P | Host Genetic Variation in the TNF and NF-?B Pathways and Prognosis in Mantle Cell Lymphoma: An Analysis of Two Studies | Yucai Wang | ![]() |
![]() |
|||
148-P | Kras and Ago2 interaction promotes initiation of plasmablastic lymphoma | Kevin Thai | ![]() |
![]() |
|||
149-P | Comprehensive epigenetic and transcriptional survey of the imprintome in normal B-cells and germinal center derived B-cell lymphomas in the framework of the MMML and ICGC MMML-Seq networks | Susanne Bens | ![]() |
![]() |
|||
150-P | Gene expression profiling and mutation analysis can aid treatment decision making in aggressive B cell lymphoma patients | Cathy Burton | ![]() |
![]() |
|||
151-P | Application of cell-of-origin subtypes determined by digital gene expression in HIV-related diffuse large B-cell lymphomas | Maria Joao Baptista | ![]() |
![]() |
|||
152-P | BIODLCL04: THE PROGNOSTIC ROLE OF CELL OF ORIGIN PROFILE, MYC, BCL2 AND TP53 IN UNTREATED POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA. | ANNALISA CHIAPPELLA | ![]() |
![]() |
|||
153-P | Prognostic significance and correlation to gene expression profile of EZH2 mutations in diffuse large B-cell lymphoma (DLBL) in two large prospective studies | Thomas Cummin | ![]() |
![]() |
|||
154-P | Preliminary evidence of a molecular predictor of tazemetostat response, beyond EZH2 mutation, in NHL patients via characterization of archive tumor and circulating tumor DNA | Stephen Blakemore | ![]() |
![]() |
|||
155-P | Array-based DNA methylome analyses of primary lymphomas of the central nervous system | Julia Vogt | ![]() |
![]() |
|||
159-P | Identification and characterisation of the lymphoma initiating cell (LIC) population in an ALCL mouse model | Anna Lena Illert | ![]() |
![]() |
|||
160-P | Oncogenic Activation of STAT3 Pathway Drives PD-L1 Expression in Natural Killer/T cell Lymphoma | Tammy Song | ![]() |
![]() |
|||
161-P | SAMHD1 is frequently involved in T-cell Prolymphocytic Leukemia (T-PLL) pathogenesis | Patricia Johansson | ![]() |
![]() |
|||
164-P | Focal skeletal 18F-FDG uptake characterizes a subset of classical Hodgkin lymphoma patients with poor outcome - A Danish-Swedish study of 209 newly diagnosed patients | Mette Abildgaard Pedersen | ![]() |
![]() |
|||
165-P | Histological verification of positive positron emission tomography findings during the follow-up of patients with mediastinal lymphoma: large experience on 96 patients | Pier Luigi Zinzani | ![]() |
![]() |
|||
166-P | SAFETY AND EFFICACY ANALYSIS OF ELDERLY PATIENTS TREATED WITHIN THE GATLA HL-05 CLINICAL TRIAL: PET adapted therapy after 3 cycles of ABVD for all stages of Hodgkin Lymphoma | Astrid Pavlovsky | ![]() |
![]() |
|||
167-P | Allogeneic transplantation in Hodgkins lymphoma after a failed autograft: long term outcomes and graft-versus-host disease free/relapse-free survival (GRFS) | Francesco Spina | ![]() |
![]() |
|||
169-P | Real life experience with brentuximab vedotin: the Italian study on 234 relapsed/refractory Hodgkins lymphoma | Pier Luigi Zinzani | ![]() |
![]() |
|||
170-P | A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy followed by 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma | Anita Kumar | ![]() |
![]() |
|||
172-P | Mortality rates remain increased in young patients with classical Hodgkin lymphoma even after years in remission: Results from a Nordic Lymphoma Group Study | Jorne Biccler | ![]() |
![]() |
|||
173-P | Predicted Cardiac and Second Cancer Risks in Hodgkin Lymphoma Patients Treated with Advanced Proton Beam Therapy Compared to Photon Radiotherapy. | Georgios Ntentas | ![]() |
![]() |
|||
174-P | Cardiac disease prediction following Hodgkin lymphoma: An EORTC Lymphoma Group and GELA follow-up study | Maja Maraldo | ![]() |
![]() |
|||
175-P | Usefulness of N-terminal brain natriuretic peptide levels and FRESCO scale for the prediction of anthracycline-induced cardiomyotoxicity in patients with Hodgkin Lymphoma | Mariana Ferraro | ![]() |
![]() |
|||
178-P | Autoimmune Disease (AID) is both a Risk Factor and a Prognostic Factor Affecting Survival in Patients with B-Cell Non-Hodgkin Lymphoma (NHL) | Ora Paltiel | ![]() |
![]() |
|||
179-P | Microenvironmental features reflecting immunocompetence are strong outcome determinants in HIV-associated lymphoma | Maja Vase | ![]() |
![]() |
|||
180-P | Outcome Prediction in Diffuse Large B-cell Lymphoma Can Be Greatly Improved by Alternative Use of Clinical Information: A Nordic Lymphoma Group Study | Jorne Biccler | ![]() |
![]() |
|||
181-P | Simultaneous Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) at the Diagnosis has similar outcome as DLBCL | Katerina Benesova | ![]() |
![]() |
|||
182-P | High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials | Patrick Reagan | ![]() |
![]() |
|||
183-P | LONG-TERM FOLLOW-UP AFTER LOCALIZED RADIOTHERAPY IN PATIENTS WITH TRANSFORMED B-CELL LYMPHOMA TREATED WITH RITUXIMAB-CONTAINING CHEMOTHERAPY | Kenji Nozaki | ![]() |
![]() |
|||
184-P | Obinutuzumab-miniCHOP for the Treatment of Elderly Unfit Patients with Diffuse Large B-Cell Lymphoma. A study of the Fondazione Italiana Linfomi. | Caterina Mammi | ![]() |
![]() |
|||
185-P | End of treatment PET-CT predicts progression free survival in DLBCL after first-line treatment: results from the Phase III GOYA study | Madeleine Wilde | ![]() |
![]() |
|||
186-P | Rituximab SC and IV plus CHOP show similar efficacy and safety in the randomised MabEase study in first-line DLBCL | Madeleine Wilde | ![]() |
![]() |
|||
187-P | R-COMP vs. R-CHOP AS FIRST-LINE THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA IN PATIENTS OLDER THAN 60 YEARS: RESULTS FROM A RANDOMIZED PHASE 2 STUDY FROM THE SPANISH GELTAMO GROUP | Juan-Manuel Sancho | ![]() |
![]() |
|||
188-P | Anthracycline Dose Intensification in Diffuse Large B-cell Lymphoma | Pengpeng Xu | ![]() |
![]() |
|||
189-P | Phase 2 randomized trial comparing standard RCHOP versus BRCAP as first line treatment in young patients with high-risk DLBCL. A study from Spanish Group GELTAMO | ANA MARQUEZ | ![]() |
![]() |
|||
191-P | Rituximab, lenalidomide, and ibrutinib alone and combined with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma | Jason Westin | ![]() |
![]() |
|||
194-P | Bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: Final analysis of a phase 2 study from GELTAMO | Alejandro Martín | ![]() |
![]() |
|||
195-P | Reduced intensity (FB2) vs reduced toxicity myeloablative (FB3-4) fludarabine/busulfan based conditioning regimens for non-Hodgkin lymphoma (NHL) allografted patients. | Amandine Le Bourgeois | ![]() |
![]() |
|||
196-P | Double-expressor lymphomas do not have inferior outcome after autologous stem cell transplant in the first line treatment. | Marie Trnkova | ![]() |
![]() |
|||
197-P | Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-associated Diffuse Large B-cell Lymphomas | Michele Merli | ![]() |
![]() |
|||
198-P | Current therapy of secondary CNS involvement in malignant lymphoma: Data from a multicenter prospective international registry | Agnieszka Korfel | ![]() |
![]() |
|||
199-P | Validation of the CNS International Prognostic Index in a Large Asian Cohort Data from the Singapore Lymphoma Study Group | yuh shan Lee | ![]() |
![]() |
|||
202-P | Dose-dense chemoimmunotherapy and CNS prophylaxis in patients with high-risk DLBCL: a comparison of Nordic CRY-04 and CHIC studies | Sirpa Leppa | ![]() |
![]() |
|||
203-P | Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy | Niels Murawski | ![]() |
![]() |
|||
204-P | Frequency of perforation & impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement: an international, multi-center retrospective study. | Collin Chin | ![]() |
![]() |
|||
205-P | Long Term Follow-Up and Update for Patients Enrolled in ECOG 1405 | Nadia Khan | ![]() |
![]() |
|||
206-P | Mantle cell lymphoma of mucosa associated lymphoid tissue: a retrospective multicenter observational study of the European Mantle Cell Lymphoma Network | Lucia Morello | ![]() |
![]() |
|||
208-P | R-CHOP / R-HDAC and rituximab maintenance results in high complete remission rate, minimal residual disease negativity, and excellent survival in elderly MCL patients | Pavel Klener | ![]() |
![]() |
|||
209-P | Maintenance rituximab improves survival in newly diagnosed mantle cell lymphoma patients: analysis of the Czech Lymphoma Study Group | Ale Obr | ![]() |
![]() |
|||
210-P | Rituximab Maintenance after Nordic Protocol (R-MaxiCHOP/HD-AraC/ASCT) Significantly Prolongs Survival in Young Mantle Cell Lymphoma Patients | Pavel Klener | ![]() |
![]() |
|||
211-P | SAKK 36/13 - Ibrutinib and bortezomib followed by ibrutinib maintenance in patients with relapsed and refractory mantle cell lymphoma: Phase I report of a Phase I/II trial | Urban Novak | ![]() |
![]() |
|||
212-P | Phase I/II clinical trial of a tumor cell vaccine followed by vaccine-primed lymphocyte infusion for patients with Mantle Cell Lymphoma | Matthew Frank | ![]() |
![]() |
|||
213-P | Obinutuzumab plus Ibrutinib in relapse/refractory mantle cell lymphoma patients: first results of the Oasis phase I trial. | STEVEN LE GOUILL | ![]() |
![]() |
|||
214-P | Rituximab maintenance after autologous stem cell transplantation in patients with mantle cell lymphoma, final result of the LyMa trial conducted on behalf the LYSA group | Steven Le Gouill | ![]() |
![]() |
|||
217-P | Progression-free survival following lenalidomide-based treatment is significantly longer in extragastric than in gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) | Barbara Kiesewetter | ![]() |
![]() |
|||
219-P | Treatment with combination of lenalidomide and rituximab achieves durable responses in a long term follow up of patients with indolent non-hodgkins lymphoma | Maria Chaudhry | ![]() |
![]() |
|||
220-P | Minimal residual disease and outcomes in relapsed/refractory follicular lymphoma (FL) in the Phase III GADOLIN trial of obinutuzumab and bendamustine vs bendamustine | Madeleine Wilde | ![]() |
![]() |
|||
221-P | R-CP chemoimmunotherapy in patients with IgM paraproteinaemic neuropathy produces improvements in functional, electrophysiological and serological outcomes. | Andrew Duncombe | ![]() |
![]() |
|||
222-P | Bendamustine-rituximab (BR) versus R-CHOP as upfront therapy for indolent B-cell lymphomas: a comparative, population-based analysis | Adam Olszewski | ![]() |
![]() |
|||
223-P | A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED-STAGE FOLLICULAR LYMPHOMA | EunJin Choi | ![]() |
![]() |
|||
224-P | Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation at rituximab era | PIERRE SESQUES | ![]() |
![]() |
|||
225-P | Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or inmunochemotherapy in Follicular Lymphoma | Ana Jiménez Ubieto | ![]() |
![]() |
|||
226-P | Autologous transplantation improves survival in patients with follicular lymphoma experiencing early therapy failure after frontline chemoimmunotherapy: A NLCS and CIBMTR analysis | CARLA CASULO | ![]() |
![]() |
|||
227-P | Minimal residual disease (MRD) in early stage follicular lymphoma can predict prognosis and drive rituximab treatment after radiotherapy | ALESSANDRO PULSONI | ![]() |
![]() |
|||
228-P | Low Grade B-cell Non-Hodgkin Lymphomas involving the Central Nervous System: An Analysis from the National Cancer Database | Priyanka Pophali | ![]() |
![]() |
|||
230-P | Patients with follicular lymphoma (FL) in maintained complete response (CR) at 30 months show a survival similar to a sex- and age-matched Spanish general population | Laura Magnano Mayer | ![]() |
![]() |
|||
231-P | POD24 and CR30 are promising surrogate endpoints for assessing the outcome of patients with advanced stage Follicular Lymphoma enrolled in the FOLL05 trial by FIL. | Martina Manni | ![]() |
![]() |
|||
232-P | Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed Follicular lymphoma in the Rituximab era | Connie Batlevi | ![]() |
![]() |
|||
233-P | Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma | Jacob Soumerai | ![]() |
![]() |
|||
234-P | Statin use and prognosis in 12,865 non-Hodgkin lymphoma patients treated in the Rituximab-era | Elsa Brnvall | ![]() |
![]() |
|||
235-P | Ibrutinib Increases the Systemic Exposure of Rituximab: Pharmacokinetic Results from the HELIOS Trial | Laurie Orloski | ![]() |
![]() |
|||
239-P | Outcomes with Bruton Tyrosine Kinase Inhibition in relapsed / refractory chronic lymphocytic leukemia / small lymphocytic lymphoma after progression on venetoclax | Mary Ann Anderson | ![]() |
![]() |
|||
240-P | Outcomes of patients post ibrutinib treatment for relapsed / Refractory CLL: A UK and Ireland analysis | George Follows | ![]() |
![]() |
|||
241-P | Ibrutinib For Relapsed / Refractory CLL: An update of the UK And Ireland Analysis Of Outcomes In 315 Patients | George Follows | ![]() |
![]() |
|||
244-P | Outcome of patients with relapsed and refractory peripheral T cell lymphoma intended for stem cell transplant | Stephen Parkin | ![]() |
![]() |
|||
245-P | A multi-center study of GLIDE chemotherapy consolidated with autologous stem cell transplantation for newly diagnosed stage IV and relapsed extranodal natural killer/T-cell lymphoma patients | Jie Ji | ![]() |
![]() |
|||
246-P | Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (R/R sALCL). A Retrospective Analysis of the Lymphoma Working Party-EBMT. | Eva Domingo Domenech | ![]() |
![]() |
|||
247-P | Risk stratification based on NCCN-IPI at the time of diagnosis in combination with post-treatment PET-CT scan for the treatment of nodal peripheral T-cell lymphoma | Ho-Young Yhim | ![]() |
![]() |
|||
252-P | Prognostic factors in patients with relapsed or refractory systemic anaplastic large T-cell lymphoma (ALCL) receiving brentuximab vedotin and outcome after treatment failure. | Yasuhiro Oki | ![]() |
![]() |
|||
253-P | Case Match Control Analysis of PROPEL Reveals a Survival Advantage for Patients with Relapsed PTCL Receiving Pralatrexate: A Novel Approach to Benchmark Drugs in Rare Diseases | Owen OConnor | ![]() |
![]() |
|||
254-P | A Post-marketing Surveillance Study of 703 Patients Treated with Chidamide for Peripheral T-cell Lymphoma (PTCL) in China HDAC Study Group of Union for China Lymphoma Investigators(UCLI) | Jian Chen | ![]() |
![]() |
|||
255-P | Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma. | Catherine Scholz | ![]() |
![]() |
|||
256-P | Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: Interim results of postmarketing all-case surveillance | Satoshi Yurimoto | ![]() |
![]() |
|||
257-P | Targeting the T-cell receptor -constant domain for immunotherapy of T-cell malignancies | Paul Maciocia | ![]() |
![]() |
|||
258-P | Development of novel, non-toxic rifamycins that reverse drug resistance in diffuse large B-cell lymphoma (DLBCL) | Steve Maxwell | ![]() |
![]() |
|||
260-P | Dual inhibition of EZH2 and HDAC is synergistic in EZH2 dysregulated lymphomas | Jennifer Lue | ![]() |
![]() |
|||
261-P | STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B-CELL NON-HODGKINS LYMPHOMAS (NHL) | Arturo Molina | ![]() |
![]() |
|||
263-P | Copanlisib in combination with anti-PD-1 induces regression in animal tumor models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors | Ningshu Liu | ![]() |
![]() |
|||
264-P | PD--1 immune checkpoint blockade improves anti--CD20 based immunotherapy in follicular lymphoma | cédric rossi | ![]() |
![]() |
|||
265-P | Characterization and integration of mantle cell lymphoma microenvironments are determinant for the development of rational targeted therapies | David Chiron | ![]() |
![]() |
|||
266-P | Effective therapy by anti-CD81 against B cell lymphomas engages both direct and indirect immune mechanisms | Shoshana Levy | ![]() |
![]() |
|||
268-P | Expression of LAG-3 defines exhaustion of intratumoral PD-1 T cells and correlates with poor outcome in follicular lymphoma | Zhizhang Yang | ![]() |
![]() |
|||
271-P | A phase I study of chimeric antigen receptormodified T cells directed against CD19 in patients with relapsed or refractoryCD19() B cell Lymphomas: interim analysis | Zhitao Ying | ![]() |
![]() |
|||
273-P | Safety and Clinical Activity of RP6530, a Dual PI3Kd/? Inhibitor, in Patients with advanced Hematologic Malignancies: Analysis of a Phase 1 Multi-center Study | Prajak Barde | ![]() |
![]() |
|||
278-P | Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-cell Lymphoma: Phase I/II Results | Jason Westin | ![]() |
![]() |
|||
280-P | The Immunologic Doublet of Lenalidomide Plus Obinutuzumab is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/II Study | Nathan Fowler | ![]() |
![]() |
|||
284-P | Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory FL or DLBCL: updated results of a phase 1b/2 study | Anne Nunn | ![]() |
![]() |
|||
285-P | YourTreatmentChoices: Fast Access to Trials Programme | George Xinarianos | ![]() |
![]() |
|||
286-P | Increasing cross-referral and recruitment to clinical trials: a new APProach | Judith Trotman | ![]() |
![]() |
|||
287-P | Oral Azacytidine (AZA) and Romidepsin (R) Reveals Promising Activity in Patients with Relapsed or Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) | Owen OConnor | ![]() |
![]() |
|||
288-P | CD70 expression in Cutaneous T cell lymphoma (CTCL) patients and mechanisms of action of ARGX-110 in skin: histopathological and clinical data | Anna Hultberg | ![]() |
![]() |
14-17 June 2017, Lugano
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|